Rockwell Medical Announces Appointment of Jesse Neri as Senior Vice President and Chief Financial Officer

Rockwell Medical, Inc. made a significant announcement on December 10, 2024, revealing the appointment of Jesse Neri as their new Senior Vice President and Chief Financial Officer, effective immediately. Neri, aged 46, will now also hold the role of Principal Financial Officer within the company.

Prior to this appointment, Neri had been serving as the Senior Vice President of Finance at Rockwell Medical since October 2023 and had been the principal accounting officer since January 2024. Neri brings a wealth of experience from his previous roles; he was the Executive Director of Finance at Hemavant Sciences and Aruvant Sciences, both clinical-stage biopharmaceutical companies within the Roivant portfolio. He also held positions at Zyla Life Sciences and Symphony Health Solutions, among others.

In connection with Mr. Neri’s employment in October 2023, Rockwell Medical entered into an Employment Agreement with him. This agreement outlines that Neri will function as an at-will employee with an annual base salary of $300,000 (subject to adjustments). Additionally, he will be eligible for year-end performance bonuses and can participate in various employee benefit plans. Neri will also receive annual long-term incentive grants, including an initial equity grant of time-based stock options.

The Employment Agreement further details the terms under which Neri’s employment may be terminated due to various circumstances including death, disability, termination without cause, or due to a change of control within the company. Neri is entitled to specific benefits and provisions based on these different termination scenarios, ensuring a structured and transparent process in such events.

In signing the Employment Agreement, Neri also agreed to Rockwell Medical’s Employee Confidentiality, Assignment of Inventions, Non-Interference, and Non-Competition Agreement, underscoring his commitment to maintaining confidentiality and adherence to the company’s policies.

This comprehensive summary of the recent appointment and employment agreement provides an insight into the strategic growth and management changes within Rockwell Medical. The full text of the Employment Agreement is available for reference. Investors and stakeholders can access this and related financial information on the company’s official SEC filings.

This news is a clear indicator of Rockwell Medical’s commitment to strengthening its leadership team and ensuring financial stewardship as it continues to navigate the evolving landscape of the healthcare industry.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Rockwell Medical’s 8K filing here.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.